Company Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs.
The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016.
Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| IPO Date | Feb 4, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Rami Elghandour |
Contact Details
Address: 25 West Watkins Mill Road Gaithersburg, Maryland United States | |
| Website | https://arcellx.com |
Stock Details
| Ticker Symbol | ACLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001786205 |
| CUSIP Number | 03940C100 |
| ISIN Number | US03940C1009 |
| Employer ID | 47-2855917 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Rami Elghandour | Chairman of the Board, Chief Executive Officer & President |
| Kate Aiken | Chief People Officer |
| Maryam Abdul-Kareem J.D., M.S. | General Counsel & Chief Legal Officer |
| Michelle Lim Gilson | Chief Financial Officer |
| Aileen Fernandes | Chief Business Officer |
| Dr. Christopher R. Heery M.D. | Chief Medical Officer |
| Dr. Heba Nowyhed Ph.D. | Chief Scientific Officer |
| Myesha Lacy | Chief Investor & Communications Officer |
| Narinderjeet Singh M.S. | Chief Technical Officer |
| Neeraj P. Teotia | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 8-K | Current Report |
| Dec 09, 2024 | 8-K | Current Report |
| Dec 05, 2024 | 4 | Filing |
| Nov 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 19, 2024 | 4 | Filing |
| Nov 14, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 4 | Filing |
| Nov 12, 2024 | 4 | Filing |